Tarek I. Hassanein, M.D., FACP, FAG, AGAF
1 clinical trials · Sponsor
◉ Watch Tarek I. Hassanein, M.D., FACP, FAG, AGAF
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics (NCT02304159) | Tarek I. Hassanein, M.D., FACP, FAG, AGAF | 2015-01-01 |
Track Tarek I. Hassanein, M.D., FACP, FAG, AGAF automatically
Every clearance here is in the API, with alerts when new ones post.